Overview
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).
In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
Description
- Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we
will identify the patients with a genomic low risk using the multigene-assay
(OncoFREE®).
- In these, ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
- Either goserelin acetate or leuprorelin Acetate is allowed.
- These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.
- Chemotherapy is omitted in these patients.
Eligibility
Inclusion Criteria:
- ER+HER2- breast cancer
- Premenopausal and age <=50
- T1 or T2
- N1 including micrometastasis
- Genomic Low Risk by OncoFREE test® (1-20)
Exclusion Criteria:
- Postmenopausal women
- ER-negative breast cancer